Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 2Thoracic 1Sarcoma 1Head & Neck 1Endocrine 1CNS 1

Conditions

Sarcoma 17Small Cell Lung Carcinoma 1Sarcoma, Synovial 1Sarcoma, Ewing 1Sarcoma, Alveolar Soft Part 1Osteosarcoma 1Neoplasm Metastasis 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Gastrointestinal Stromal Tumors 1Desmoid Tumors 1Carcinoma, Non-Small-Cell Lung 1Bone Neoplasms 1

Interventions

pembrolizumab 11Gemcitabine 10Doxorubicin 10Cyclophosphamide 9Specimen Handling 8Nivolumab 8Ibandronic Acid 8pazopanib 7Radiosurgery 6Magnetic Resonance Spectroscopy 6Imatinib Mesylate 6Biopsy 6Bevacizumab 6Irinotecan 5regorafenib 4Zoledronic Acid 4Ipilimumab 4Ifosfamide 4Fluorouracil 4Docetaxel 4Cetuximab 4sargramostim 3conatumumab 3cemiplimab 3Sunitinib 3Radiation 3Paclitaxel 3Leucovorin 3Cryosurgery 3Cisplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × anlotinib × Sarcoma × Clear all
NCT03416517 2019-02-15

Anlotinib and Irinotecan for Ewing Sarcoma

Peking University People's Hospital

Phase 1/2 Unknown
47 enrolled
Sarcoma

Neoplasm Metastasis, Sarcoma, Ewing

Data powered by HemOnc (CC BY 4.0) Colophon âš¡